Clinical Trial Update: Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety and potential activity of recombinant interleukin-15 in combination with nivolumab and ipilimumab in patients with treatment…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors
• Treatment-refractory Cancers

Drugs mentioned

• Interleukin-15 (recombinant) (Interleukin-15)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Solid Tumors, Treatment-Refractory Cancers | Phase 1 | Status: COMPLETED | Results posted: 2025-12-03